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Neurobiology of Disease
The Complement System Component C5a Produces Thermal
Hyperalgesia via Macrophage-to-Nociceptor Signaling That
Requires NGF and TRPV1
XLeonid P. Shutov,1* XCharles A. Warwick,1* Xiaoyu Shi,2 Aswini Gnanasekaran,1 Andrew J. Shepherd,1,3
Durga P. Mohapatra,1,3 XTrent M.Woodruff,4 J. David Clark,2 and Yuriy M. Usachev1
1Department of Pharmacology, University of Iowa, Iowa City, Iowa 52242, 2Department of Anesthesia, Veterans Administration Palo Alto Healthcare
System and Stanford University, Palo Alto, California 94305, 3Department of Anesthesiology, Washington University Pain Center, Washington University
School of Medicine, St. Louis, Missouri 63110, and 4School of Biomedical Sciences, University of Queensland, St. Lucia, Queensland 4072, Australia
The complement cascade is a principal component of innate immunity. Recent studies haveunderscored the importance of C5a andother
components of the complement system in inflammatory and neuropathic pain, although the underlying mechanisms are largely un-
known. In particular, it is unclear how the complement systemcommunicateswith nociceptors andwhich ion channels and receptors are
involved. Here we demonstrate that inflammatory thermal and mechanical hyperalgesia induced by complete Freund’s adjuvant was
accompaniedbyC5aupregulation andwasmarkedly reducedbyC5a receptor (C5aR1) knock-out or treatmentwith theC5aR1 antagonist
PMX53. Direct administration of C5a into themouse hindpaw produced strong thermal hyperalgesia, an effect that was absent in TRPV1
knock-outmice, andwas blocked by the TRPV1 antagonist AMG9810. Immunohistochemistry ofmouse plantar skin showed prominent
expression of C5aR1 in macrophages. Additionally, C5a evoked strong Ca2 mobilization in macrophages. Macrophage depletion in
transgenic macrophage Fas-induced apoptosis mice abolished C5a-dependent thermal hyperalgesia. Examination of inflammatory me-
diators following C5a injection revealed a rapid upregulation of NGF, a mediator known to sensitize TRPV1. Preinjection of an NGF-
neutralizing antibody or Trk inhibitor GNF-5837 prevented C5a-induced thermal hyperalgesia. Notably, NGF-induced thermal
hyperalgesiawasunaffectedbymacrophagedepletion. Collectively, these results suggest that complement fragmentC5a induces thermal
hyperalgesia by triggering macrophage-dependent signaling that involves mobilization of NGF and NGF-dependent sensitization of
TRPV1. Our findings highlight the importance ofmacrophage-to-neuron signaling in pain processing and identify C5a, NGF, and TRPV1
as key players in this cross-cellular communication.
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Introduction
The complement system is a critical part of innate immunity and
plays an important role in the recognition and clearance of patho-
gens. It consists of30 soluble andmembrane-bound proteins that
are rapidly mobilized through a cascade of enzymatic reactions and
participate in host defenses through a range ofmechanisms, includ-
ing direct killing of bacteria, facilitation of phagocytosis, the recr-
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Significance Statement
This study provides mechanistic insight into how the complement system, a key component of innate immunity, regulates the
development of pain hypersensitivity. We demonstrate a crucial role of the C5a receptor, C5aR1, in the development of inflam-
matory thermal andmechanical sensitization. By focusing on themechanisms of C5a-induced thermal hyperalgesia, we show that
this process requires recruitment of macrophages and initiation of macrophage-to-nociceptor signaling. At the molecular level,
we demonstrate that this signaling depends onNGFand ismediated by the heat-sensitive nociceptive channel TRPV1. This deeper
understanding of how immune cells and neurons interact to regulate pain processing is expected to facilitate mechanism-based
approaches in the development of new analgesics.
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uitment and activation of immune cells, va-
sodilation, and an increase in vascular per-
meability (Monk et al., 2007; Wagner and
Frank, 2010; Ricklin and Lambris, 2013;
Holers, 2014). Recent studies have high-
lighted the importance of the complement
cascade in the nervous system, particularly
in the regulationof nociceptor function and
pain processing (Griffin et al., 2007; Jang et
al., 2010; Ren and Dubner, 2010; LaCroix-
Fralish et al., 2011). An upregulation of sev-
eral components of the complement system
in the periphery, DRG, and spinal cord has
been implicated in inflammatory and neu-
ropathic pain, whereas inhibition of the
complement cascade has been reported to
produce analgesic effects in several animal
models of chronic pain (Twining et al.,
2005; Griffin et al., 2007; Jang et al., 2011; LaCroix-Fralish et al.,
2011).
Among the many components of the complement system,
C5a is perhaps best established as a potent regulator of pain pro-
cessing. C5a is a 74 amino acid polypeptide that is rapidly pro-
duced in response to injury or infection by proteolytic cleavage of
complement protein C5. Each of the three major complement
activation pathways (i.e., classical, lectin, and alternative) can
lead to the generation of C5a that acts via a canonical G-protein
coupled receptor, C5aR1 (also known as C5aR or CD88), and
possibly another recently characterized receptor, C5aR2 (also
known as C5L2 or GPR77), to enhance immune responses and
produce many other biological effects (Brennan et al., 2012; Klos
et al., 2013; Li et al., 2013; Ricklin and Lambris, 2013; Kemper et
al., 2014). Numerous studies suggest the importance of C5a in
various chronic pain conditions. Indeed, increased production of
C5a has been reported in several pathological states associated
with pain, including rheumatoid arthritis, pancreatitis, inflam-
matory bowel disease, and surgical trauma (Fosse et al., 1987;
Roxvall et al., 1989; Jose et al., 1990; Kiener et al., 1998; Grant et
al., 2002; Bhatia, 2005).Upregulation ofC5 andC5a has also been
shown in the animalmodels of postsurgical pain and neuropathic
pain (Griffin et al., 2007; Jang et al., 2011), whereas direct admin-
istration of C5a produced prominent thermal and mechanical
sensitization in rodents (Levine et al., 1985; Jang et al., 2010, 2011;
Moriconi et al., 2014). Notably, genetic deletion of the C5a pre-
cursor, C5, reduced neuropathic pain (Griffin et al., 2007), and
C5aR1 knock-out (KO) decreased thermal and mechanical sen-
sitization induced by incision (Liang et al., 2012). Moreover, the
administration of C5aR1 antagonists produced analgesic effects
in various models of inflammatory and neuropathic pain (Clark
et al., 2006; Ting et al., 2008; Jang et al., 2011; Moriconi et al.,
2014), highlighting the therapeutic potential of pharmacological
targeting of C5a and C5aR1 for chronic pain management.
Despite the growing evidence for the crucial role of C5a in
chronic pain, the mechanisms underlying its pronociceptive ac-
tions have not been delineated. In particular, it is unclear how
C5a and other complement components signal to nociceptors,
and which nociceptive ion channels or receptors they target.
Here, by using genetic and pharmacological tools, we identify
transient receptor potential vanilloid 1 (TRPV1) as a key molec-
ular target of C5a-induced signaling that leads to thermal hyper-
algesia. We also demonstrate that macrophages are required for
C5a-induced thermal hyperalgesia, suggesting that macrophage-
to-nociceptor communication is involved. Finally, we show that
NGF, a well-established modulator of TRPV1, is also required
and acts downstream of C5a and upstream of TRPV1 in the pro-
posed signaling cascade.
Materials andMethods
Animals. All experiments involving the use of mice and the procedures
used therein were approved by the University of Iowa Institutional Ani-
mal Care and Use Committee and were performed in strict accordance
with the National Institutes of Health Guide for the care and use of labo-
ratory animals. Every effort was made to minimize the number of mice
used and their suffering. Male C57BL/6J or BALB/C (6–10 weeks of age)
mice were housed with food and water ad libitum under a 12 h light/dark
cycle. C5aR1 KO (#006845; BALB/C), TRPV1 KO (#003770; C57BL/6J),
macrophage Fas-induced apoptosis (MAFIA) (#005070; C57BL/6J), and
phospholipase C2 (PLC2) KO (#018064; C57BL/6J) mice were pur-
chased from The Jackson Laboratory.
Macrophage depletion. For drug-inducible macrophage depletion ex-
periments, we used transgenic MAFIA mice (Burnett et al., 2004). These
mice express a drug-inducible suicide gene under the control of the
macrophage/monocyte-specific colony-stimulating factor (CSF) 1 re-
ceptor (c-fms) promoter, whose activation by the dimerizing compound
AP20187 (Clontech catalog #635069) triggers Fas-induced apoptosis in
macrophages and dendritic cells (Burnett et al., 2004;O’Brien et al., 2012;
Cho et al., 2014). MAFIA mice do not seem to be depleted of microglia
following systemic administration of AP20187, most likely due to poor
penetration of the compound through the blood–brain barrier (Burnett
et al., 2004; Wang et al., 2013). Male MAFIA mice were administered
either 2 mg/kg of AP20187 dissolved in vehicle (10% PEG-400 and 1.7%
Tween 80 in PBS) or vehicle alone on a daily basis via intraperitoneal
injection for 5 d. Behavioral testing and immunohistochemistry were
performed 6 d after the first injection of AP20187 or vehicle.
Behavioral testing. Thermal and mechanical sensitivity was measured
by Hargreaves test and von Frey filament threshold calculation, respec-
tively, as described previously (Schnizler et al., 2008; Jang et al., 2010; Loo
et al., 2012; Mickle et al., 2015b). Briefly, mice were acclimatized to the
behavioral testing chambers for 2 h per day beginning 3 d before testing.
The Hargreaves testing apparatus was an IITC Plantar Analgesia Meter
(IITC Life Sciences) with the glass tabletop heated to a thermo-neutral
temperature. Nociceptive thermal sensitivity wasmeasured by focusing a
beam of light on the plantar surface of the hindpaw to generate heat. The
time required for the stimulus to elicit withdrawal of the hindpaw (paw
withdrawal latency) was recorded using the programmable digital timer
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Figure 1. C5aR1 KO significantly reduces inflammatory thermal and mechanical hyperalgesia induced by CFA. A, B, CFA was
injected into the plantar surface of either wild-type or C5aR1 KO (BALB/C background) mouse hindpaw. Thermal (A; paw-
withdrawal latency; 14wild-type and 16 C5aR1 KOmice) andmechanical (B; mechanical threshold; 20wild-type and 20 C5aR1 KO
mice) sensitivities were measured before (baseline time 0) and at various times after the CFA injection. *p 0.05, relative to
wild-type mice (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). **p 0.01, relative to wild-type mice
(two-way repeated-measures ANOVA with Bonferroni’s post hoc test).
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of the IITC Plantar Analgesia Meter. Baseline latency was determined
shortly (15–30min) before drug administration, by averaging the results
of three tests separated by a 5 min interval. For the von Frey testing,
mechanical sensitivity was assayed by calculating the 50% response
threshold to 5 presentations each of 0.04, 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, and
2 g von Frey filaments (Stoelting). After baseline measurements were
taken, either 500 ng recombinant mouse C5a in 10l PBS, 10 ng NGF in
10 l PBS, or 20 l of Complete Freund’s adjuvant (CFA) suspension
(1 mg/ml) was injected into the plantar surface of the hindpaw using
a 33-gauge needle (26 gauge in the case of CFA) coupled to a Hamil-
ton syringe. NGF neutralizing antibody, IgG (control), or GNF-5837
was administered into the plantar skin of the
hindpaw 30 min before injection of C5a or
NGF. For systemic administration of the
C5aR1 antagonist, PMX53 (Woodruff et al.,
2002; Proctor et al., 2006; Woodruff et al.,
2006), the drug was dissolved in sterile 5%
glucose/water solution and delivered subcu-
taneously into the skin of the back of mouse
at a 3 mg/kg dose in a 100 l volume 1 h
before behavioral testing. Efficacy of this
dose of PMX53 has been extensively vali-
dated (Woodruff et al., 2002; Proctor et al.,
2006; Jang et al., 2011; Benson et al., 2015).
The individual performing the be-
havioral measurements was blinded to the
drug treatment and mouse genotype where
applicable.
ELISA measurements. C5a (500 ng in 10 l
PBS) was administered subcutaneously into
the hindpaw as described above.Mice (C57BL/
6J) were killed by cervical dislocation under
isoflurane anesthesia at various time points af-
ter injection: 0 (control/baseline), 0.5, 1, 2, 3,
and 24 h (4 mice/time point). A sharp scalpel
was used to remove a 3  8 mm area of skin
from the plantar surface of the hindpaw; the
skin sample was then cut into small pieces us-
ing scissors, and then homogenized in buffer
containing 1 Complete Protease Inhibitor
Mixture (Roche Applied Science), 100 mM
Tris/HCl, 1 M NaCl, 4 mM EDTA, 2% Triton
X-100, 0.1% sodiumazide using a Polytron ho-
mogenizer device. Homogenates were then
centrifuged at 12,000 g for 15min at 4°C, and
the supernatant was collected and used to per-
form a Pierce BCA total protein assay (Thermo
Scientific) as described by the manufacturer.
Samples were then frozen at80°C until used
for ELISA. NGF and prostaglandin E2 (PGE2)
measurements were performed using NGF
(MDMillipore) andPGE2 (CaymanChemical)
ELISA kits, respectively, according to the
manufacturer’s recommendations. Multiplex
ELISAwasperformedusing theStanfordHuman
Immune Monitoring Core 26-plex (Stanford
University, Palo Alto, CA) and tested for the
following cytokines and growth factors:
eotaxin (CCL11), granulocyte colony-stimulating
factor (G-CSF), granulocyte-monocyte colony-
stimulating factor (GM-CSF), interferon-
(IFN-), IFN--inducible protein 10 (IP-10/
CXCL10), interleukins IL-1, IL-1, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-10, IL-12-P40, IL-12-P70, IL-
13, IL-17, and IL-23, keratinocyte-derived
chemokine (KC/CXCL1), monocyte chemoat-
tractant protein 1 (MCP-1/CCL2), monocyte
chemoattractant protein 3 (MCP-3/CCL7),
macrophage inflammatory protein 1 (MIP-
1/CCL3), RANTES (CCL5), tumor necrosis
factor  (TNF-), transforming growth factor  (TGF-), and vascular
endothelial growth factor (VEGF).
For the experiments involving C5a measurements, 20 l CFA (1 mg/
ml) was administered subcutaneously into the hindpaw as described
above. Mice (C57BL/6J) were killed by cervical dislocation under isoflu-
rane anesthesia at various time points after injection: 1, 3, and 8 d. Base-
line measurements were performed using naive C57BL/6J mice. The
skin was removed as described above and then frozen at 80°C until
used for a C5a ELISA (R&D Systems) performed according to the
manufacturer’s recommendations.
Figure2. C5aR1 significantly contributes to thermal andmechanical hyperalgesia inducedby CFA.A, Levels of C5a in skin tissue
fromnaivewild-type C57BL/6Jmice (baseline) or after injectionof CFAweremeasuredby ELISAat the indicated timepoints (n5
or 6mice/time point). **p 0.01, relative to baseline (one-way ANOVAwith Bonferroni’s post hoc test).B, CFA-induced thermal
hyperalgesia was compared between three groups of C57BL/6J wild-type mice. The first group received daily administration of
vehicle control (black circles;n8), the secondgroup receiveddaily administration of the C5aR1antagonist PMX53 (red triangles;
n 7), and the third group received a single injection of PMX53 (1 h before testing) on day 3 after CFA injection (green squares;
n 8). *p 0.05, relative to control (two-way repeated-measures ANOVAwith Bonferroni’s post hoc test). Greenand redasterisks
indicatePMX53 (daily) andPMX53 (day3)mousegroups, respectively.C,D, CFA-inducedmechanical hyperalgesia is significantly reduced
after administration of PMX53. CFA was injected into the plantar surface of wild-type (C57BL/6J) mice; and then 1 d after CFA injection,
eitherasalinecontrol (n10)orPMX53(n11)wasadministered.AfterCFA,day1waschosenbasedontheC5aR1KOfindings(Fig.1B)
asthetimeatwhichCFA-inducedmechanicalsensitizationwasmostsignificantlyreducedinC5aR1KOcomparedwithwild-typemice.Paw
withdrawal thresholdsweremeasuredeitherbeforeor1and3hafterPMX53 injection.C,Highlightedarea is replotted forclarity inDusing
an extended time scale. *p 0.05, relative to control (two-way repeated-measures ANOVAwith Bonferroni’s post hoc test). E, Thermal
hyperalgesia inducedby CFA injectionwas reducedby PMX53 administration 3 d after CFA injection inwild-type (BALB/C;n 9) but not
C5aR1KO (n9)mice. Thermal sensitivitywas testedonday3after CFA immediatelybefore (time0h) and1hafter PMXadministra-
tion. F, Mechanical hyperalgesia induced by CFA injection was reduced by PMX53 administration 1 d after CFA injection in wild-type
(BALB/C;n8)butnot C5aR1KO (n9)mice.Mechanical sensitivitywas testedonday1after CFA immediatelyprior (time0h) and
1 and 3 h after PMX administration. ***p 0.001, relative to baseline (time 0 h; E, F ) (two-way repeated-measures ANOVA with
Bonferroni’spost hoc test).
Shutov, Warwick et al. • C5a Induces Hyperalgesia via Macrophages and TRPV1 J. Neurosci., May 4, 2016 • 36(18):5055–5070 • 5057
Immunohistochemistry. Immunohistochem-
ical staining and analysis were performed as
previously described (Loo et al., 2012; Shep-
herd and Mohapatra, 2012; Mickle et al.,
2015b). In brief, adult male mice were killed
and immediately underwent intracardiac per-
fusion with 4% PFA in 0.1 M phosphate buffer
(PB). After fixation, 3 mm plantar punches
were taken using a Harris Micro-Punch (Ted
Pella), postfixed for 16 h in 4% PFA with 5%
picric acid, incubated for 16 h in decalcification
buffer (10% EDTA, 0.07% glycerol, and 15%
sucrose in 0.1 M PB), 16 h in cryoprotectant
(30% sucrose in 0.1 M PB), embedded in Opti-
mal Cutting Temperature (Sakura Finetek),
frozen, and sectioned into 40 m sections us-
ing a cooled cryostat (CM3050 S; Leica Micro-
systems). The tissue slices were blocked for 1 h
with blocking buffer containing either 10%
goat (Sigma) or donkey serum (The Jackson
Laboratory) and 0.3% Triton X-100 in 0.1 M
PB. Tissue slices were then incubated with pri-
mary antibodies diluted in blocking buffer for
24 h, washed 3 times with blocking buffer, and
then incubated with secondary antibodies for
2 h. After staining, the sections were mounted
on microscope slides with ProLong Gold
(Invitrogen). We used the following primary
antibodies: rat anti-C5aR1 (1:500; clone
10/92, catalog #MCA2456GA AbD Serotec),
rat anti-F4/80 (1:500; clone A3-1; catalog
#MCA497GA; AbD Serotec), rabbit anti-IBA1
(1:500; catalog #019-19741; Wako Chemicals),
and guinea pig anti-TRPV1 C terminus (1:
1000; catalog #GP14100; Neuromics). All of
these primary antibodies were described previ-
ously (Hume et al., 1984; Imai et al., 1996; Guo
et al., 1999; Sasmono et al., 2003; Soruri et al.,
2003; Tschernig et al., 2007; Brennan et al.,
2015). AlexaFluor-488- and AlexaFluor-555-
conjugated goat or donkey secondary antibodies (Invitrogen) were used
at a 1:1000 dilution. Images were captured using an Olympus BX61WI
microscope equipped with the Fluoview 300 laser-scanning confocal im-
aging system and either a 20 objective (NA 0.75; Olympus) or a 60
oil-immersion objective (NA 1.40; Olympus). For quantification, IBA1-
stainedmacrophages were imaged by an investigator blinded to the treat-
ment conditions, and quantified using ImageJ software.
Primary macrophage culture. Primary macrophages were isolated and
cultured as described by Ray and Dittel (2010). Fluid thioglycolate me-
dium (4%) (BD Biosciences) was prepared by boiling until the thiogly-
colate was dissolved, and then autoclaved. After cooling, 3 ml of 4%
thioglycolate was injected into the peritoneal cavity of C57BL/6J,
BALB/C, PLC2 KO, or C5aR1 KO mice. Six days after injection, the
mice were killed, and 5ml of ice-cold PBS with 3% FBS was injected into
the peritoneal cavity with a 27G needle. The peritoneumwas gently mas-
saged for 1min to loosen and detach cells. The fluid was then removed by
inserting a 25G needle into the peritoneum and slowly drawing out the
fluid. Another 5 ml of PBS 3% FBS was then injected, the peritoneum
was againmassaged, and the fluid was removed in the samemanner. The
cells were then spun down at 1500 RPM for 8 min, the supernatant was
removed, and the cells were resuspended in Complete Macrophage Me-
dium (ScienCell Research Laboratories). The cells were then plated at 6
different dilutions on poly-D-lysine (Sigma)-coated glass coverslips using
8 mm cloning cylinders and kept in a 5% CO2 incubator at 37°C for 1 h
before adding additional growth media. The cloning cylinders were re-
moved, the cells were washedwith growthmedia to remove nonadherent
cells, and then the appropriate cell density was determined by micros-
copy as yield of macrophages versus nonadherent cells varies. A density
of75% confluency was chosen, and remaining cells were plated at that
density. Cells were incubated for 24–48 h before being used for calcium
imaging, immunocytochemistry or RT-PCR.
Transfection of primary macrophages. Macrophages were isolated as
described and plated on 100 mm culture dishes for 24 h. The macro-
phages were then transfected using a Nucleofector Kit for Mouse Mac-
rophages (catalog #VAPA-1009; Lonza) according to themanufacturer’s
protocol. Macrophages are a notoriously difficult to transfect cell type;
and after experimentation with different transfection techniques, we
found that an Amaxa/Lonza nucleofection-based protocol provided
35% transfection efficiency. This was substantially better than the re-
sults obtained using Lipofectamine 2000 (ThermoFisher) and magneto-
fection (Oz Biosciences), which yielded 2% efficiency after extensive
optimization (data not shown).
For our transfection protocol, cultured primary macrophages were
briefly washed with PBS, placed in 3 ml 0.05% trypsin for 30 min, gently
scraped, diluted with 7 ml growth media, and counted. Cells were made
into aliquots of 1.0 106 cells/transfection and spun down at 200 g for
10 min. The cells were resuspended in 100 l Nucleofector solution 
supplement  3 g of plasmid DNA, transferred to an electroporation
cuvette, and then transfected using the Y-001 program of the Amaxa
Nucelofector II device (Lonza). Culture media (600l) was added to the
cuvette and then transferred to a microcentrifuge tube with 650 l of
media. Cells were then plated on six poly-D-lysine-coated glass coverslips
using 8 mm cloning cylinders (210 l per cylinder) and were removed
after 1 h after adding 3 ml of growth media to the 6-well dish. For each
transfection (106 cells/transfection), we used either 1 g of each
shRNA construct plus 1 g of pmaxGFP (Lonza) or 2 g pLKO.1 empty
vector DNA (GE Dharmacon) plus 1 g of pmaxGFP. A set of shRNA
plasmids (in pLKO.1 vector) targeting mouse PLC3 were purchased
Figure 3. C5a-induced thermal hyperalgesia depends on C5aR1 and TRPV1.A, Thermal sensitivitywasmeasured before (base-
line time 0 h) and at various times after injection of 0 (Sham), 10, 100, 500, or 2500 ng C5a (in 10l) into the plantar surface of
the hindpaw of wild-type (C57BL/6J) mice (n 4 or 5 mice per dose). B, Thermal sensitivity (paw withdrawal latency) was
measured before (baseline time 0 h) and at various times after injection of C5a (500 ng in 10l) into the plantar surface of the
hindpaw of either wild-type (BALB/C; black circles; n 7) or C5aR1 KO mice (red squares; n 6). ***p 0.001, relative to
wild-type mice (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). C, D, Thermal sensitivity was measured
before (baseline time 0 h) and after injection of C5a either alone (500 ng; black circles and red squares) or in combination with
the TRPV1 antagonist AMG9810 (67 ng AMG9810 500 ng C5a; green triangles) into the plantar surface of a mouse hindpaw.
Three groups of mice were examined: (1) wild-typemice (C57BL/6J) injected with C5a alone (black circles; n 18); (2) wild-type
mice injectedwith the combination of C5a and AMG9810 (green triangles; n 11); and (3) TRPV1 KOmice injectedwith C5a (red
squares; n 8).D, Data are from the same experiments as in C but are normalized to baseline values for each animal. *p 0.05,
relative to wild-type mice treated with C5a (two-way repeated-measures ANOVA with Bonferroni’s post hoc test).
**p 0.01, relative to wild-type mice treated with C5a (two-way repeated-measures ANOVA with Bonferroni’s post hoc test).
***p 0.001, relative to wild-typemice treated with C5a (two-way repeated-measures ANOVAwith Bonferroni’s post hoc test).
Green and red asterisks indicate wild-type/C5aAMG and TRPV1KO/C5a mouse groups, respectively.
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from GE Dharmacon (catalog #RMM4534-EG18797; developed by the
Broad Institute’s RNAi Consortium/TRC). Using the NIH-3T3 cells, we
identified two shRNA plasmids that produced the highest knockdown
(see Fig. 6F ), shRNA#1 (ID: TRCN0000076916; 5	-TTTCCAAGGGA
AACTCATCAG-3	) and shRNA #2 (ID: TRCN0000076914; 5	-TTT
GATGAACTTACTCCCGCG-3	). Ca2 imaging was performed 48 h
after transfection. Transfected cells were identified by maxGFP fluores-
cence. The described approach resulted in95% cotransfection as veri-
fied by cotransfecting macrophages with mCherry and maxGFP and
quantifying cells that coexpress both fluorescent proteins (data not
shown).
Calcium imaging. The standard extracellular HEPES-buffered HBSS
(HH buffer) contained the following (in mm): 140 NaCl, 5 KCl, 1.3
CaCl2, 0.4MgSO4, 0.5MgCl2, 0.4 KH2PO4, 0.6 NaHPO4, 3 NaHCO3, 10
glucose, and 10 HEPES, pH 7.35 with NaOH (310 mOsm/kg with su-
crose). Primary macrophages were incubated for 25 min with 2 M of
fura-2AM(Invitrogen) at room temperature (22°C). Cells were placed in
a flow-through chamber mounted on the stage of an inverted IX-71
microscope (Olympus) andwashed for 10minwithHHbuffer before the
experiment. C5a and other drugs were applied by continuous bath su-
perfusion. Fluorescence was alternately excited at 340 and 380 nm (12
nm bandpass) using the Polychrome V
monochromator (T.I.L.L. Photonics) and a
20 objective (NA 0.75; Olympus). Emitted
fluorescence was collected at 510 nm (84 nm
bandpass) using an IMAGO CCD camera
(T.I.L.L. Photonics). Pairs of 340/380 nm im-
ages were sampled at 1 Hz. The fluorescence
ratio (r F340/F380) was converted to [Ca
2]i
according to the formula [Ca2]i Kd(R
Rmin)/(Rmax  R) (Grynkiewicz et al., 1985).
The dissociation constant (Kd) used for fura-2
was 275 nM (Shuttleworth and Thompson,
1991). Rmin, Rmax, and  were determined by
applying 10M ionomycin in either Ca2-free
buffer (with 1 mM EGTA) or HH buffer
(1.3 mM Ca2). Calibration constants were as
follows: Rmin  0.22, Rmax  3.07, and  
6.05. Fluorescence was corrected for back-
ground, as determined by an area that did not
contain a cell. Data were processed using TILL-
visION (T.I.L.L. Photonics) and the GraphPad
Prism 6 software, and are presented as
mean
 SEM.
Immunocytochemistry. Cells were washed
with PBS and then fixed with 4% PFA for
15–20 min at room temperature. Cells were
then washed 3 times with PBS for 5 min/wash,
incubated for 30 min in blocking buffer (5%
goat serum and 0.1% Triton X-100 in PBS),
and incubated with rat anti-C5aR1 (1:500;
clone 10/92, AbD Serotec) and rabbit anti-
IBA1 (1:500; Wako Chemicals). The cells were
washed 3 times with blocking buffer and then
incubated with AlexaFluor-488 goat anti-rat
andAlexaFluor-555 goat anti-rabbit secondary
antibodies (1:1000; Invitrogen) in blocking
buffer at room temperature and in darkness for
30 min. Cells were washed with PBS 3 times
and then mounted on a slide using anti-fade
reagent Fluoromount-G (Southern Biotech-
nology). Images were captured using anOlym-
pus BX61WI microscope equipped with the
Fluoview 300 laser-scanning confocal imaging
system and a 60 oil-immersion objective
(NA 1.40, Olympus) as previously described
(Schnizler et al., 2008).
Western blotting. Cells were collected in ho-
mogenization buffer (100 mM NaCl, 50 mM
Tris/HCl, 0.1 mM EDTA, and 1% Triton
X-100) containing a protease inhibitormixture (Sigma, 1:50) and a phos-
phatase inhibitor (Sigma, 1:100) and homogenized with a 25-gauge nee-
dle. Cell lysates were then diluted with Laemmli reducing buffer and
heated at 95°C for 5 min before loading 20 g of protein/sample into an
8%SDS-polyacrylamide gel. Proteins in SDS-PAGE gels were transferred
to nitrocellulose membranes (Bio-Rad) using the transfer buffer (1.5 g
Tris-HCl, 7.2 g glycine, and 150 ml MeOH dissolved in 1000 ml H2O).
Then, the membrane was incubated with a blocking solution composed
of 5% skimmilk in TBS (20mMTris-HCl, pH 7.5, and 150mMNaCl) for
1 h, washed briefly with TBS, and then incubated with primary antibod-
ies for 4 h. The following primary antibodies were used: rabbit anti-
PLC2 (1:500; catalog #sc-206; Santa Cruz Biotechnology) and rabbit
anti-PLC3 (1:500; catalog #sc-403 Santa Cruz Biotechnology). Both
antibodies were extensively described and validated (Ali et al., 1997;
Tordjmann et al., 1998; Runnels et al., 2002; Galeotti et al., 2006). GRP75
was used as a loading control and probed with amonoclonal anti-GRP75
antibody (1:2000; clone N52A/42; Neuromab). The membranes were
then washed with TBS and incubated either with HRP-conjugated goat
anti-rabbit antibodies (1:1000; catalog #A0545, Sigma) or with HRP-
conjugated goat anti-mouse antibodies (1:2000; catalog #48-146-H; An-
Figure 4. C5aR1 in the skin is expressed primarily in macrophages. Immunohistochemical analysis was performed in skin
sections from themouse hindpawas described inMaterials andMethods, and the imageswere obtained using either a 20 (A,B;
NA 0.75; Olympus) or a 60 (C, D; oil-immersion, NA 1.40; Olympus) objective. A, B, Expression of C5aR1 (red) and IBA1
(green; a molecular marker of macrophages) in skin from wild-type (A) or C5aR1 KO (B) mice. C, Expression of IBA1 (green) and
another macrophage marker, F4/80 (red), in the skin. D, Expression of TRPV1 (green; primary afferent fibers) and IBA1 (red;
macrophages) in the skin. Left, Single Z-plane. Right, Z-stack composite image (Z 15m; Z-step 0.25m).
Shutov, Warwick et al. • C5a Induces Hyperalgesia via Macrophages and TRPV1 J. Neurosci., May 4, 2016 • 36(18):5055–5070 • 5059
tibodies). Membranes were then washed and developed with ECL HRP
detection kit (GEHealthcare). All the experiments were repeated 3–5 times.
RT-PCR. Total RNA was isolated from primary mouse macrophages
24–48 h after plating or from mouse (C57BL/6J) hippocampi using the
RNase easyPlusMiniKit (QIAGEN)with addedon-columnDNase-I diges-
tion according to the manufacturer’s recommendations. The purified RNA
was then reverse transcribed and amplified using the one-step RT-PCR kit
(QIAGEN). The following primer sets were used: GAPDH forward: 5	-
ACCACAGTCCATGCCATCAC-3	; GAPDH reverse: 5	-CACCACCCT
GTTGCTGTAGCC-3	; NGF forward: 5	-ACAGGCAGAACCGTA
CACAG-3	; NGF reverse: 5	-TGACGAAGGTGTGAGTCGTG-3	; C5aR1
forward: 5	-CAGGGACCTTCAGGCATCCATT-3	; C5aR1 reverse: 5	-
TTTGAGCGTCTTGGTGGAGC-3	. RT-PCRs were performed using a Bi-
ometra T3 thermocycler. TheNoRT control reaction did not have a reverse
transcription stepandwasusedas a control for contaminationwithgenomic
DNA. The amplified PCR products were separated by electrophoresis on a
2% agarose gel and were detected using ethidium bromide.
Reagents. Recombinant mouse C5a, GNF-5837, AMG9810, U73122,
U73343, o-3M3FBS, m-3M3FBS, thapsigargin, cyclopiazonic acid, and
gallein were purchased from R&D Systems/Tocris Bioscience. CFA was
purchased from Sigma; fura-2 AM was obtained from Invitrogen. NGF
neutralizing antibody and IgG control were purchased from Ex Biolog-
icals (catalog #L148M and 0G11, respectively). NGF was from AbD Se-
rotec, and AP20187 (B/B homodimerizer) was from Takara/Clontech.
PMX53 (AcF-[OPdChaWR]acetate salt) was synthesized as reported
previously (March et al., 2004), purified by reversed-phase high-
performance liquid chromatography, and fully characterized by mass
spectrometry.
Statistical analysis.Data are expressed as mean
 SEM. The following
tests were used for analyzing the data: unpaired Student’s t (comparison
Figure5. C5aproduces a strong [Ca 2]i response inmacrophages.A, Immunostaining inmouseprimarymacrophages shows coexpressionof IBA1 (red) andC5aR1 (green).B, Bright-field image
and three images color-coded for [Ca 2]i represent the same field of mouse primarymacrophages loadedwith fura-2. The color-coded images show the distribution of [Ca
2]i in macrophages at
rest, and at 5 and 15 s after 100 nM C5a was applied. C, Concentration dependence of [Ca 2]i responses to C5a in macrophages. [Ca
2]i recording was performed simultaneously from several
individual macrophages (each cell represented by a different color) in response to 1, 10, or 100 nM C5a applied for 1 min. The [Ca 2]i responses to each concentration of C5a were recorded using
different coverslips with macrophages. D–G, Representative [Ca 2]i recordings demonstrating the effects of Ca
2-free extracellular buffer (supplied with 0.1 mM EGTA) (D), SERCA inhibitor
cyclopiazonic acid (10M; E), structurally distinct SERCA inhibitor thapsigargin (1M; F ), andG inhibitor gallein (10M;G) on [Ca 2]i elevations induced by 10 nM C5a (1min) inmacrophages.
H, Bar graph summarizes the effects of Ca 2-free extracellular solution, cyclopiazonic acid, thapsigargin, galleon, and C5aR1 KO on the amplitude of [Ca 2]i responses in macrophages evoked by
C5a application (10 nM, 1 min). ***p 0.001, relative to control (one-way ANOVA with Bonferroni’s post hoc test) (n 54–170 cells). Primary macrophages for immunostaining and all of the
[Ca 2]i recordings were obtained from wild-type C57BL/6J mice, except those obtained from C5aR1 KO mice (H, green bar; BALB/C background). The amplitude of C5a-induced (10 nM, 1 min)
[Ca 2]i elevations inmacrophages fromwild-type BALB/Cmice (799
 62 nM; n 25; data not shown)was similar to that inmacrophages fromwild-type C57BL/6Jmice (891
 29 nM; n 170;
p 0.21, unpaired Student’s t test).
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of 2 groups), one-way ANOVA with Bonferroni’s post hoc test (compar-
ison of 2 groups), or two-way repeated-measures ANOVA with Bon-
ferroni’s post hoc test (time coursewith comparison of 2 ormore groups).
A value of p  0.05 was considered statistically significant in all cases.
Statistical analyseswere performedusing theGraphPadPrism6 software.
Results
C5aR1 significantly contributes to thermal hyperalgesia in the
CFAmodel of inflammatory pain
We first examined the role of C5aR1 in the development and
maintenance of inflammatory pain induced by CFA (Stein et al.,
1988; Gregory et al., 2013). Intraplantar injection of CFA in wild-
type mice produced long-lasting thermal (Fig. 1A) and mechan-
ical (Fig. 1B) hypersensitivity. CFA-induced thermal hyperalgesia
was significantly reduced inC5aR1KOmice, showing recovery to
baseline levels by day 3 after CFA injection (Fig. 1A). C5aR1 KO
mice also exhibited a significant reduction in mechanical sensiti-
zation (Fig. 1B). Assessment of C5a levels by ELISA revealed a
significant and prolonged increase at the site of CFA-induced
inflammation, with full recovery by day 8 after injection
(Fig. 2A). We also examined the effects of the C5aR1 antagonist
PMX53 on CFA-induced thermal hyperalgesia (Woodruff et al.,
2002, 2006; Proctor et al., 2006). As shown in Figure 2B, daily
administration of PMX53 to wild-type animals markedly di-
minished thermal hyperalgesia (green squares) compared with
control (vehicle-treated; black circles) animals. Furthermore,
acute treatment with PMX53 on day 3 after CFA injection
rapidly and reversibly reduced thermal hyperalgesia (Fig. 2B,
red triangles). Similarly, PMX53 administration 1 d after CFA
injection significantly reduced mechanical hyperalgesia (Fig.
2C,D). In contrast, administration of PMX53 in C5aR1 KO
mice did not affect CFA-induced thermal and mechanical hy-
peralgesia, which is consistent with the selectivity of PMX53
for C5aR1 under our experimental conditions (Fig. 2E,F ).
These data suggest that C5aR1 plays a critical role in the de-
velopment and maintenance of thermal and mechanical hy-
peralgesia during inflammation.
Figure 6. C5a-induced [Ca 2]i elevation inmacrophages depends on PLC signaling.A–E, Representative [Ca
2]i recordings demonstrate the effects of PLC inhibitor U73122 (1M;A), inactive
analog of U73122, U73343 (1M; B), PLC activator, m-3M3FBS (25M; C), its inactive variant, o-3M3FBS (25M; D), and PLC2 KO (E) on C5a-induced Ca 2mobilization in macrophages. F,
Western blot analysis was used to examine expression of PLC3 in wild-type macrophages (lane 5) and NIH-3T3 cells (lanes 1–4) transfected with shRNA against PLC3 (lanes 1 and 2), PLC3
(overexpression [OE]; lane 3), or empty vector (pLKO.1; lane 4). GRP75was used as a loading control.G, Western blot analysis shows expression of PLC2 inwild-type (lane 1), but not in PLC2 KO
(lane 2)mice (GRP75 as a loading control).H, I, Representative [Ca 2]i recordingswere obtained from PLC2 KOmacrophages transfected either with empty vector (pLKO.1)maxGFP (n 16;
H ) or PLC3 shRNA#1  #2  maxGFP (n  13; I ). Transfected macrophages were identified by maxGFP fluorescence. J, Bar graph summarizes the effects of U73122, U73343,
m-3M3FBS, o-3M3FBS, PLC2 KO, empty vector, and PLC3 shRNAs on the amplitude of C5a-induced [Ca 2]i elevations in macrophages. **p 0.01, ***p 0.001, relative to control
(wild-type macrophages, n 170; replotted from Fig. 5H ) (one-way ANOVA with Bonferroni’s post hoc test). ##p 0.01, relative to naive PLC2 KO macrophages (n 13–134 cells)
(one-way ANOVA with Bonferroni’s post hoc test).
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C5a-induced thermal hyperalgesia is
mediated by TRPV1
Next, we aimed to identify mechanisms
that are responsible for C5aR1-dependent
thermal hyperalgesia. In these experi-
ments, thermal hyperalgesia was pro-
duced by intraplantar injection of C5a
(Fig. 3) as previously described (Jang et
al., 2010, 2011). We first examined a dose
dependence of C5a with intraplantar in-
jection of 0 (sham), 10, 100, 500, or 2500
ng of C5a in wild-type mice (Fig. 3A). As
500 ng showed no significant difference
from2500 ng and lastedmuch longer than
100 ng, 500 ng was chosen as an optimal
dose for further experiments. Two recep-
tors for C5a have been identified, C5aR1
and C5aR2 (Monk et al., 2007; Klos et al.,
2013; Kemper et al., 2014). We found that
C5a-induced thermal hyperalgesia was
absent in C5aR1 KO mice (Fig. 3B), sug-
gesting that C5aR1 is responsible for the
effects of C5a injection. This is consistent
with a previous report that the C5aR1 an-
tagonist PMX53 blocked C5a-induced
thermal hyperalgesia (Jang et al., 2011).
Next, we sought to identify a nocicep-
tive ion channel or receptor that could
mediate the hyperalgesic effect of C5a.
TRPV1 was chosen as a likely candidate
given that it is a polymodal nonselective cation channel that is
expressed in primary nociceptors and is activated by noxious
heat, acidic pH, and lipid-derived endovanilloids. The channel is
also critical for development of inflammatory thermal hyperalge-
sia (Caterina et al., 1997; Caterina et al., 2000; Davis et al., 2000;
Bhave andGereau, 2004; Immke andGavva, 2006; Patapoutian et
al., 2009; Mickle et al., 2015a). We thus tested its role in the C5a
pronociceptive effect using TRPV1 KO mice (Caterina et al.,
2000). We observed a small increase in baseline paw withdrawal
latency in TRPV1 KO mice (Fig. 3C) consistent with previous
reports of mild deficit in heat sensitivity in these animals (Ca-
terina et al., 2000; Vardanyan et al., 2009). More importantly,
C5a-induced thermal hyperalgesia was nearly abolished in the
TRPV1 KO mice (Fig. 3C,D). Furthermore, coadministration of
the TRPV1 antagonist AMG9810 blocked the pronociceptive ef-
fect of C5a in wild-type animals (Fig. 3C,D). These data indicate
that TRPV1 is a critical effector of the C5a-induced signaling that
leads to thermal hyperalgesia.
Macrophages are required for C5a-induced
thermal hyperalgesia
To identify the cell type(s) that mediates the effect of C5a, we
examined C5aR1 expression in the glabrous skin of the mouse
hindpaw. Using a C5aR1-specific antibody, we found a distinct
immunoreactivity in skin sections from wild-type mice, but not
in those from C5aR1 KO mice (Fig. 4A,B). The majority of the
cells that were immunoreactive for C5aR1 also expressed the
macrophage marker IBA1 (Imai et al., 1996; Vega-Avelaira et al.,
2009; Kwon et al., 2013). The IBA1-positive cells expressed an-
other macrophage marker, F4/80, confirming that the described
cells are macrophages (Davies et al., 2013) (Fig. 4C). These mac-
rophages were found in close proximity to TRPV1-positive fibers
that innervate the skin (Fig. 4D), consistent with a potential role
of these cells in activating nociceptive signaling.
We also examined C5aR1 expression in macrophages at a
functional level. Intracellular Ca2 signals control many aspects
of macrophage activation and function, including migration and
cytokine expression and secretion (Onozaki et al., 1983; Under-
wood and Riches, 1992; Yamamoto et al., 2008; Fric et al., 2012;
Desai and Leitinger, 2014). Therefore, we used Ca2 imaging in
primary mouse macrophages to test their response to C5a. Like
macrophages in the skin, the cultured primary macrophages
prominently expressed C5aR1 (Fig. 5A). We found that brief
application of C5a (1–100 nM, 1 min) produced a dose-
dependent increase in the intracellular Ca2 concentration
([Ca2]i) in all macrophages (Fig. 5B,C). This C5a-evoked ele-
vation of [Ca2]i was absent in macrophages obtained from
C5aR1 KO mice, indicating that the effect was mediated by
C5aR1. Removing extracellular Ca2 reduced the amplitude
of C5a-induced [Ca2]i response by30% (Fig. 5D). Depletion
of intracellular Ca2 stores using the inhibitors of the sarcoen-
doplasmic reticulumCa2-ATPase (SERCA), cyclopiazonic acid
(10 M), or thapsigargin (Tg; 1 M), produced a much stronger
effect, diminishing the [Ca2]i response by 80% and 95%,
respectively (Fig. 5D,E). These findings suggest that intracellular
Ca2 stores are a major source of C5a-induced Ca2 mobiliza-
tion in macrophages.
C5aR1 is a Gi-coupled receptor whose activation triggers
multiple signaling events, including G-dependent activation
of PLC (Monk et al., 2007; Klos et al., 2013). We focused on the
G-PLC signaling pathway because it is well known to lead to
the synthesis of inositol 1,4,5-trisphosphate (IP3) and IP3-
induced release of Ca2 from intracellular stores in various cell
types (Berridge et al., 2003; Clapham, 2007). We found that the
C5a-induced [Ca2]i increase in macrophages was significantly
Figure 7. Macrophage depletion abolishes C5a-induced thermal hyperalgesia. A, B, IBA1 staining of plantar skin sections
obtained fromMAFIA mice treated with vehicle (A) or AP20187 (B) for 5 d. C, Quantification of IBA1 immunoreactivity in plantar
skin of the hindpaw after 5 d of treatment with vehicle or AP20187. ***p 0.001 (unpaired Student’s t test).D, Pawwithdrawal
latencies after injection of C5a into the plantar surface of MAFIAmice treated with vehicle (black squares; n 5) or AP20187 (red
circles; n 11). ***p 0.001, relative to vehicle (two-way repeated-measures ANOVA with Bonferroni’s post hoc test).
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diminished by application of either the G inhibitor gallein (10
M; Fig. 5G) (Lehmann et al., 2008) or the PLC inhibitor U73122
(1 M; Fig. 6A) (Bleasdale et al., 1990). The inactive analog of
U73122, U73343, had no effect on C5a-induced [Ca2]i eleva-
tions (1 M; Fig. 6B). Similar to C5a, a selective PLC activator,
m-3M3FBS (25 M; Fig. 6C), but not its inactive analog
o-3M3FBS (25 M; Fig. 6D), produced [Ca2]i increase in mac-
rophages that was blocked by depleting intracellular Ca2 stores
with 1MTg. Indeed, under control conditions, the amplitude of
m-3M3FBS-elicited [Ca2]i elevation was 1043 
 90 nM (n 
45), whereas after a pretreatment with Tg it was diminished to
137 
 44 nM (n  22; p  0.001, unpaired Student’s t test).
Furthermore, treatment with m-3M3FBS, but not with
o-3M3FBS, prevented a further [Ca2]i elevation upon C5a ap-
plication (Fig. 6C,D), suggesting that C5a and the PLC activator
m-3M3FBS use a common signaling pathway leading to [Ca2]i
increase in macrophages.
Previous studies have reported that the PLC isoforms 2 and
3 are primarily responsible for C5a-induced signaling in mac-
rophages (Wang et al., 2008; Rebres et al., 2011). Using the
PLC2- and PLC3-specific antibodies, we also found that both
PLC isoforms are expressed in macrophages (Fig. 6F,G). Exam-
ination of cultured macrophages from PLC2 KO mice showed
that the C5a-induced [Ca2]i response in
these cells was reduced by 50% com-
pared with that in wild-type macrophages
(Fig. 6E, J). An additional shRNA-based
knockdown of PLC3 in PLC2 KOmac-
rophages virtually eliminated (94% re-
duction compared with wild-type
macrophages) the C5a-induced [Ca2]i
elevation inmacrophages (Fig. 6 I, J). Col-
lectively, these data suggest that C5a pro-
duces a strong [Ca2]i response in
macrophages by triggering G- and
PLC-dependent Ca2 release from in-
tracellular (most likely IP3-sensitive)
Ca2 stores, as well as Ca2 entry via the
plasma membrane.
Next, we tested the role of macro-
phages in C5a-induced thermal hyperal-
gesia by using the MAFIA mouse, a
transgenic model of drug-inducible mac-
rophage ablation (Burnett et al., 2004).
These mice express a suicide gene that
leads to c-Fas ligand-mediated apoptosis
and is controlled by the macrophage/
monocyte-specific promoter c-fms (Yue et
al., 1993; Sasmono et al., 2003; Burnett et
al., 2004). Daily administration of the
transgene activator, AP20187, to MAFIA
mice for 5 d decreased macrophage stain-
ing (IBA1) in the plantar skin by 85% rel-
ative to vehicle-treated controls (Fig.
7A–C). In vehicle-treated MAFIA mice,
intraplantar injection of C5a elicited a
rapid and strong thermal hyperalgesia
(Fig. 7D, black circles) similar to that ob-
served in wild-type mice (Fig. 3). In
contrast, intraplantar injection of C5a
produced no changes in thermal sensitiv-
ity in the macrophage-depleted MAFIA
mice (Fig. 7D, red squares). Thus, resident
macrophages (and potentially monocytes) are required for the
development of C5a-induced thermal hyperalgesia.
NGF plays a critical role in C5a-induced thermal hyperalgesia
Based on the data described above, a plausible scenario is that
subcutaneously administered C5a acts on macrophages in the
skin to trigger macrophage-to-nociceptor signaling that ulti-
mately leads to TRPV1 sensitization and the development of
thermal hyperalgesia. To identify signaling molecules that might
mediate this cross-cellular communication, we examined how
intraplantar injection of C5a alters the expression profiles of cy-
tokines and other inflammatory mediators in the skin at the site
of injection, using a mouse multiplex cytokine analysis kit and
ELISA. We found that C5a injection induced a time-dependent
upregulation of numerous cytokines, as well as NGF and PGE2
(Fig. 8; Table 1). Given our finding that TRPV1 plays a key role in
C5a-induced thermal hyperalgesia, we focused our attention on
inflammatorymediators that are known to sensitize this receptor,
such as PGE2, NGF, IL-6, TNF-, MCP-1 (also known as CCL2),
and MIP-1 (also known as CCL3) (Lopshire and Nicol, 1998;
Zhang et al., 2005a, b; White et al., 2007; Constantin et al., 2008;
Jung et al., 2008; Khan et al., 2008; Schnizler et al., 2008; And-
ratsch et al., 2009; Russell et al., 2009). Among these mediators,
Figure 8. Intraplantar injection of C5a elevates numerous inflammatory mediators. Time-dependent changes in skin levels of
selected inflammatory factors are shown before (time 0 h) and at various time points after C5a injection for IL-6 (A), TNF- (B),
PGE2 (C), NGF (D), MCP-1/CCL2 (E), and MIP-1/CCL3 (F ). The complete dataset is shown in Table 1. Horizontal dotted lines
indicate the baseline levels for eachmediator. Vertical dotted lines indicate the 0.5 h time point after C5a injection, at which time
thermal hyperalgesia became significant (Figs. 3, 7). Among these mediators, NGF showed the fastest (peak at 0.5 h) increase in
response to C5a injection. *p 0.05, relative to baseline (one-way ANOVA with Bonferroni’s post hoc test). **p 0.01, relative
to baseline (one-way ANOVA with Bonferroni’s post hoc test). ***p 0.001, relative to baseline (one-way ANOVA with Bonfer-
roni’s post hoc test). n 4 independent experiments/time point.
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only expression of NGF paralleled the rapid development of C5a-
induced thermal hyperalgesia (30 min) in behavioral testing
(Figs. 3, 7). Indeed, NGF levels reached their peak within 30 min
of C5a injection (Fig. 8D). In contrast, all other inflammatory
mediators were upregulated at a much slower rate, showing es-
sentially no increase at 30 min and reaching their peak values
within 2–3 h after C5a injection (Fig. 8; Table 1). Thus, the rapid
time course of NGF upregulation combined with the fact that
NGF sensitizes TRPV1 through multiple signaling mechanisms
(Chuang et al., 2001; Zhang et al., 2005b; Stein et al., 2006; Zhu
and Oxford, 2007), and that it is expressed and released by mac-
rophages (Mallat et al., 1989; Garaci et al., 1999;Marcinkiewicz et
al., 1999; Obata et al., 2002), makes NGF a likely candidate for
mediating the C5a-induced thermal hyperalgesia. Consistent
with the latter findings, RT-PCR analysis demonstrated thatNGF
was expressed in our primary cultures of mouse macrophages
(Fig. 9A).
To determine the role of NGF in C5a-induced thermal hyper-
algesia, we first examined its effect on thermal sensitivity. We
found that intraplantar injection of NGF in wild-type mice in-
duced strong thermal hyperalgesia that lasted for at least 3 h (Fig.
9B). As in the case of C5a (Fig. 3), the effect of NGF was absent in
TRPV1 KO mice (Fig. 9B). Thus, TRPV1 is a crucial effector of
signaling by both C5a and NGF in the context of thermal hyper-
algesia. Next, we examined the effects of an NGF-neutralizing
antibody (anti-NGF) that had been validated by others (Wild et
al., 2007; Cheng et al., 2009; Cheng et al., 2010), and found that it
prevented NGF-induced thermal hyperalgesia (data not shown).
Moreover, administering anti-NGF, but not a control IgG, 30
min before C5a administration blocked C5a-induced thermal
hyperalgesia (Fig. 9C). This finding validates the critical role of
NGF in mediating the hyperalgesic effect of C5a (Fig. 9C). Nei-
ther IgG nor anti-NGF treatment affected the baseline (before
C5a injection) paw withdrawal latency (Fig. 9C).
NGF is thought to sensitize TRPV1 via the tropomyosin-
related kinase A (TrkA) receptor (Chuang et al., 2001; Zhang et
al., 2005b; Zhu and Oxford, 2007). Therefore, we also tested the
role of Trk signaling in C5a-induced thermal hyperalgesia. Be-
cause of the lack of commercially available isoform-selective Trk
inhibitors (Wang et al., 2008; McCarthy and Walker, 2014), we
used a potent pan-Trk inhibitor, GNF-5837 (Albaugh et al.,
2012), in these experiments. As a positive control, we de-
monstrated that pretreatment with GNF-5837 inhibited
NGF-induced thermal hyperalgesia (Fig. 9D). We found that
GNF-5837 inhibited the effect of C5a in a dose-dependent man-
ner (Fig. 9E).
Finally, if NGF functions downstream of macrophage
activation in the C5a-induced signaling cascade, its prono-
ciceptive action should theoretically be independent of
macrophages. To test this idea, we examined the effect of in-
traplantar administration of NGF in macrophage-depleted
mice. We found that NGF produced a rapid and strong ther-
mal hyperalgesia in macrophage-depleted (AP20187-treated)
MAFIA mice and that this effect was similar to that produced
by NGF in wild-type mice (Fig. 10). In contrast, C5a ad-
ministration had no effect in macrophage-depleted mice
(Figs. 7, 10).
Together, these data indicate that NGF is required for C5a-
induced thermal hyperalgesia and that it acts downstream of
macrophage activation and upstream of TRPV1.
Table 1. C5a-induced changes in the levels of inflammatorymediators in the skina





































































































































































































aAll measurements were made using WT C57BL/6J mice.
bControl values are from naive mice. All values are given in pg analyte/mg total protein as mean
 SEM.
*p 0.05, **p 0.01, ***p 0.001, relative to control (baseline) values (one-way ANOVA with Bonferroni’s post hoc test). n 4 independent experiments/time point.
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Discussion
In this study, we identify mechanisms that underlie C5a-induced
thermal hyperalgesia (Fig. 11). Our findings suggest that C5a
generated in response to injury or inflammation acts via
macrophages to initiate an intercellular signaling cascade that
ultimately causes sensitization of nociceptors to heat. This
macrophage-to-nociceptor signaling cascade recruits TRPV1 as a
key nociceptive channel that mediates C5a-induced thermal hy-
peralgesia. In turn, NGF serves as an essential mediator in this
cascade that acts downstream of C5aR1 and macrophages, sensi-
tizing TRPV1 to heat via previously identified signaling mecha-
nisms coupled to TrkA activation (Chuang et al., 2001; Zhang et
al., 2005b; Zhu and Oxford, 2007). The pathway described here
represents a novel signaling module that underlies interactions
between the complement system and nociceptive neurons in elic-
iting pain hypersensitivity (Fig. 11).
There has been growing recognition of the importance of the
complement cascade in the nervous system (Brennan et al., 2012;
Stephan et al., 2012). Several of its components contribute to the
regulation of neuronal development, synapse plasticity, and re-
modeling (Stephan et al., 2012). However, excessive activation of
the complement system and overproduction of C5a, as well as of
C3a, have been linked to neurotoxic processes that occur after
stroke, spinal cord injury, and in several chronic neurological
disorders, such as multiple sclerosis, amyotrophic lateral sclero-
sis, and Alzheimer’s disease (Veerhuis et al., 2011; Brennan et al.,
2012).
The role of the complement system is particularly important
in regulating nociceptor function and pain processing (Li et al.,
2007; Ren and Dubner, 2010). Many components of the comple-
ment cascade are upregulated in chronic pain states, and phar-
macologic or genetic targeting of the complement system
produce analgesic effects (Clark et al., 2006; Levin et al., 2008;
Wang et al., 2011; Moriconi et al., 2014). Here, we demonstrated
an important role of the complement fragment C5a in the CFA
model of inflammatory pain. CFA-induced hyperalgesia was ac-
Figure 9. NGF signaling is required for C5a-induced thermal hyperalgesia. A, RT-PCR shows expression of C5aR1 and NGF in primary macrophages (the housekeeping gene GAPDH serves as a
control). No RT indicates the negative control reaction for which a reverse transcription step was omitted. Hippocampal mRNAwas used as a control for NGF expression (Collins and Crutcher, 1985;
Shelton and Reichardt, 1986; Ayer-LeLievre et al., 1988).B, Intraplantar injection of NGF (10 ng) produced thermal hyperalgesia inwild-type (C57BL/6J)mice (black circles; n 6), but not in TRPV1
KO mice (red squares; n 8). ***p 0.001, relative to wild-type (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). C, Intraplantar administration of C5a (500 ng) induced
thermal hyperalgesia (black triangles; n 10), and this was blocked by pretreatmentwith the NGF neutralizing antibody (1g; 30min before C5a injection; red circles; n 16), but not by control
IgG (1g; 30 min before C5a injection; gray squares; n 10). All tests were performed using wild-type C57BL/6J mice. *p 0.05, relative to C5a (two-way repeated-measures ANOVA with
Bonferroni’spost hoc test). ***p0.001, relative to C5a (two-way repeated-measures ANOVAwithBonferroni’spost hoc test).D, NGF-induced thermal hyperalgesia (10ngNGF; black squares;n
4) was prevented by pretreatment with the Trk inhibitor, GNF-5837 (500 ng; 30min before NGF injection; red squares; n 4). All tests were performed usingwild-type C57BL/6J mice. *p 0.05,
relative to NGFSham (two-way repeated-measures ANOVAwith Bonferroni’s post hoc test). **p 0.01, relative to NGFSham (two-way repeated-measures ANOVAwith Bonferroni’s post hoc
test). E, Thermal hyperalgesia induced by intraplantar C5a (500 ng; black circles; n 8) was diminished by pretreatment (30 min before C5a injection) with the Trk inhibitor GNF-5837 in a
dose-dependent manner (50 ng, red squares, n 11; 500 ng, green triangles, n 7). All tests were performed using wild-type C57BL/6J mice. *p 0.05, relative to C5aSham (two-way
repeated-measures ANOVA with Bonferroni’s post hoc test). ***p 0.001, relative to C5aSham (two-way repeated-measures ANOVA with Bonferroni’s post hoc test). Red and green asterisks
indicate the 50 and 500 ng doses of GNF-5837, respectively.
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companied by significant upregulation of C5a in the affected area
(Fig. 2A), and both KO and pharmacological inhibition of C5aR1
markedly diminished CFA-induced thermal and mechanical hy-
peralgesia, although with a slightly different time dependence
(Fig. 1). This difference suggests that C5a/C5aR1 play distinct
roles during the onset and maintenance of CFA-induced me-
chanical and thermal sensitization, respectively. Although the
doses of C5a required to induce thermal hyperalgesia (Fig. 3) are
consistent with the previous work (Jang et al., 2010; Moriconi et
al., 2014), they exceed the levels of C5a found in the skin after
incision (Jang et al., 2011) or CFA treatment (Fig. 2A) (1–1.7
ng/mg protein). However, a number of confounding factors,
such as C5a diffusion, its rapid metabolism by serum and cell-
surface peptidases, and C5a internalization upon binding to its
receptor (Oppermann and Go¨tze, 1994; Monk et al., 2007; Man-
they et al., 2009), help to explain why administration of relatively
high doses of C5a is required. Overall, our findings corroborate
previous studies that highlight a critical role of C5a in pain pro-
cessing (Levine et al., 1985; Clark et al., 2006; Griffin et al., 2007;
Jang et al., 2011; Liang et al., 2012; Moriconi et al., 2014).
How does C5a produce a state of pain hypersensitivity? Our
results suggest that resident macrophages are the first cells to
respond toC5a elevation in the periphery, and that they aremajor
players in mediating the pronociceptive effects of C5a. First, us-
ing the C5aR1 KO-validated antibody, we showed that in skin
tissue C5aR1 was present almost exclusively in macrophages
(Fig. 4). Second, using Ca2 imaging, we demonstrated that
functional C5aR1 is expressed in primary macrophages. Specifi-
cally, C5aR1 activation was coupled to a robust G- and PLC-
dependent [Ca2]i response (Figs. 5, 6). Third, and most
importantly, conditional ablation of macrophages in transgenic
mice expressing a suicide gene in macrophages/monocytes abol-
ished C5a-induced hyperalgesia (Fig. 7). It has been previously
proposed that the pronociceptive action of C5a depends on neu-
trophils (Ting et al., 2008). This report relied on systemically
administered cytotoxic agent vinblastine to deplete neutrophils.
However, this agent is highly toxic to a broad range of cell types
in addition toneutrophils and is known to kill many other im-
mune cells, including monocytes and macrophages (Chen and
Schooley, 1970; Martin et al., 1981). In contrast, the MAFIA
mouse model used in our study allows specific and reversible
elimination ofmonocytes andmonocyte-derived cells (e.g., mac-
rophages), but not of neutrophils or other immune cells (Burnett
et al., 2004; Lindauer et al., 2009; Cho et al., 2014). By treating
MAFIA mice with the dimerizing compound AP20187, we
achieved85% depletion of resident skin macrophages (Fig. 7).
Macrophage-depleted mice displayed normal baseline sensitivity
to noxious heat (Fig. 7D) and developed strong NGF-induced
thermal hyperalgesia (Fig. 10), suggesting that the described
treatment did not impair the ability of these mice to sense and
respond to noxious heat. Yet, C5a-induced sensitization to heat
was eliminated by macrophage ablation. Combined with the ob-
servation that subcutaneous C5aR1 is expressed primarily in
macrophages, these findings imply that macrophages are essen-
tial for C5a-induced thermal hyperalgesia. Future studies will
determine whether macrophages also play a crucial role in C5a-
induced mechanical sensitization.
Figure 10. Macrophages are not necessary for NGF-induced thermal hyperalgesia. Heat
sensitivity was examined before (baseline time 0 h) and after intraplantar injection of NGF
(10 ng) in macrophage-depletedMAFIAmice (red circles; n 5) and wild-type C57BL/6J mice
(black squares; n 8). **p 0.01, relative to baseline (two-way repeated-measures ANOVA
with Bonferroni’s post hoc test). ***p  0.001, relative to baseline (two-way repeated-
measuresANOVAwithBonferroni’spost hoc test). Black and redasterisks indicatewild-type and
AP20187-treatedMAFIAmice, respectively. Heat sensitivity before and after intraplantar injec-
tion of C5a in macrophage-depleted MAFIA mice is shown for comparison (green triangles;
n 8; replotted from Fig. 7D).
Figure 11. Proposed model describes the signaling pathways activated by C5a in macro-
phages and nociceptors in the periphery to produce pain hypersensitivity. Activation of the
complement cascade in response to injury, infection, or inflammation leads togenerationof C5a
amongother complement products. C5a activates C5aR1 inmacrophages,which triggers G-
and PLC-dependent robust Ca 2 mobilization from intracellular (most likely IP3-sensitive)
Ca 2 stores. Although not tested in ourwork, it has been reported that C5a induces IP3 synthe-
sis in macrophages (Roach et al., 2008). C5a-induced macrophage activation results in mobili-
zation of NGF and NGF/TrkA-dependent sensitization of TRPV1 in nociceptive fibers to heat.
Gray arrows indicate additional signaling pathways and immune cell types (neutrophils and
mast cells) that can be affected by C5a but were not specifically tested in our work.
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Macrophages have been implicated in various aspects of in-
flammatory and neuropathic pain (Sorkin and Schafers, 2007;
Ren and Dubner, 2010). They can profoundly affect nociceptor
excitability by releasing soluble factors that either activate or sen-
sitize nociceptive neurons. Our findings suggest that NGF serves
as a crucial mediator of macrophage-to-nociceptor signaling in
the case of C5a-induced thermal hyperalgesia. First, NGF is ex-
pressed inmacrophages (Figure 9A) (Mallat et al., 1989; Garaci et
al., 1999; Marcinkiewicz et al., 1999). Second, out of a broad
panel of inflammatory mediators (28 total) tested in our work,
onlyNGFwas rapidly upregulated in the affected area in response
to C5a, reaching its maximumwithin 30 min after the C5a injec-
tion (Fig. 8; Table 1). This time course parallels the rapid devel-
opment of C5a-induced thermal hyperalgesia (Figs. 3, 7, 9, 10).
Other inflammatory mediators monitored in the same assay ei-
ther reached their peak levels at much later times (2–3 h after C5a
injection) or were not affected by C5a (Fig. 8; Table 1). Third,
subcutaneously administered NGF mimicked the development
of thermal hyperalgesia triggered by C5a, including its critical
dependence on TRPV1 (Figs. 3, 7, 9, 10). Thus, C5a and NGF
target the same nociceptive channel. Fourth, and most impor-
tantly, C5a-induced thermal hyperalgesiawas nearly abolished by
pretreatmentwith anNGF-neutralizing antibody (Fig. 9C). Fifth,
a Trk inhibitor, GNF-5837, strongly diminished the effect of C5a
(Fig. 9E). Finally, NGF-induced thermal hyperalgesia was insen-
sitive tomacrophage depletion (Fig. 10), indicating thatNGF acts
downstream of macrophages in the C5a-induced pronociceptive
signaling cascade (Fig. 11).
The finding that NGF serves as a critical mediator of C5a
hyperalgesic signaling is consistent with the importance of NGF
in many aspects of acute and chronic pain (Stucky et al., 1999; Ji
et al., 2002; Pezet and McMahon, 2006). On a long-time scale
(days/weeks), NGF contributes to pain hypersensitivity by regu-
lating expression of nociceptive ion channels and neuropeptides,
by triggering oxidative mechanisms, and by stimulating aberrant
axonal sprouting (Pezet and McMahon, 2006; Mantyh et al.,
2011; Eskander et al., 2015). On a short-time scale (seconds/
minutes), NGF sensitizes nociceptors to heat by regulating the
surface expression and activation properties of TRPV1 (Chuang
et al., 2001; Zhang et al., 2005b). It is likely that NGF-dependent
potentiation of TRPV1 is an essential component of the C5a-
induced signaling that ultimately leads to heat sensitization de-
scribed here (Fig. 11). Indeed, TRPV1 was required for the
hyperalgesic effects of C5a (Fig. 3), and NGF acted downstream
of C5a and upstream of TRPV1 (Fig. 9). Mechanisms underlying
the NGF-dependent sensitization of TRPV1 have been well es-
tablished by others, and hence have not been additionally
investigated in our work. They involve activation of the phospha-
tidylinositol 3-kinase and PLC signaling cascades downstream of
TrkA, which facilitates TRPV1 trafficking to the plasma mem-
brane and also sensitizes the receptor to heat, capsaicin, and other
activating stimuli (Chuang et al., 2001; Zhang et al., 2005b; Zhu
and Oxford, 2007).
Our findings that NGF is required for C5a-induced thermal
hyperalgesia do not rule out a potential involvement of other
inflammatory mediators upregulated by C5a (Fig. 8; Table 1).
Indeed, some of these mediators, such as TNF-, IL-1, IL-6,
MCP-1, MIP-1, and PGE2, are known to be secreted by mac-
rophages and to sensitize nociceptive neurons by acting on
TRPV1 and other ion channels (Nathan, 1987; Gold et al.,
1996; Marchand et al., 2005; Ji et al., 2014). Therefore, it is
possible that, in addition to NGF, some of these mediators also
contributed to the observed hyperalgesic effects of C5a,
although likely at later time points (Fig. 8). Future studies
will determine their roles in the pronociceptive effects of
C5a.
In conclusion, we have shown that the complement system
product C5a induces a hyperalgesic response by triggering
macrophage-to-nociceptor signaling and by recruiting two
prominent painmolecules, NGF andTRPV1. Pharmacologic tar-
geting of C5aR1 may prove to be a useful strategy for treating
various chronic pain conditions, including those associated with
aberrant activity of NGF and TRPV1.
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